Type to search

NEC OncoImmunity Acquires VAXIMM's Neoantigen Vaccine Development Assets | Pharmtech Focus
Transgene and NEC Announce Positive Preliminary Data from Phase I Studies of TG4050, a Novel Individualized Neoantigen Cancer Vaccine | Pharmtech Focus